

International Society for Pharmacoeconomics  
and Outcomes Research



MEETING

STARTS

13.00

THURSDAY

DECEMBER

TENTH

Inaugural  
*European*  
Conference

**EXPANDED PROGRAM**

CONFERENCE BEGINS DECEMBER 10, 1998 AT 13.00

*jointly sponsored*

by the

International Society for

Pharmacoeconomics and Outcomes Research

and the

University of Cologne

December 10, 11, and 12, 1998

Renaissance Köln Hotel, Cologne, Germany



---

# Inaugural *European* Conference

## CONFERENCE CO-CHAIRS

Jonathan Cooke MPharm, PhD

South Manchester University Hospitals, Manchester, UK

Peter G. Davey MD, FRCP

MEMO, University of Dundee, Dundee, Scotland

Alan L. Hillman MD, MBA

University of Pennsylvania, School of Medicine, Philadelphia, PA, USA

Karl W. Lauterbach MD, ScD

Institute for Health Economics at the University of Cologne,  
Cologne, Germany

## SCIENTIFIC COMMITTEE

### FACULTY

### INSTITUTION

Werner Brouwer MD

The Netherlands

Michael Drummond PhD

University of York, Centre for Health Economics, York, UK

Livio Garattini MD

CESAV Centre for Health Economics, Institute for Pharmacological  
Research, Ranica, Italy

Bengt G. Jönsson MA, PhD

Stockholm School of Economics, Stockholm, Sweden

Thomas Kurscheid MD, MPH

Institute for Health Economics at the University of Cologne,  
Cologne, Germany

Frank Peys

Belgium Institute for Health Economics, Brussels, Belgium

Claude Le Pen PhD

University Paris-Dauphine, Paris, France

Hugo Robays

University Hospital Gent, Gent, Belgium

J.Matthias Graf von Schulenberg PhD

Centre for Health Economics  
and Health System-HSR,  
University of Hannover,  
Hannover, Germany

Joan Rovira PhD

SOIKOS, Department of  
Economics, University of  
Barcelona, Barcelona, Spain

Herbert Zöllner PhD

World Health Organization,  
Copenhagen, Denmark



---

# Inaugural *European* Conference

## PRE-CONFERENCE ISPOR SHORT COURSES

Thursday, December 10, 1998

### PRE-CONFERENCE ISPOR SHORT COURSES (concurrent courses)

8.00 - 12.00

#### PHARMACOECONOMICS

Economic analyses (cost-effectiveness, cost-benefit, cost-utility, and cost-minimization) including the design of these studies will be presented. Discounting, decision analytic modeling, utilities and the merits of prospective versus retrospective studies will be discussed. Examples of recently published pharmacoeconomic analyses will be critiqued. *This course is designed for individuals with little experience with pharmacoeconomic evaluations.*

8.00 - 12.00

#### DECISION ANALYSIS IN HEALTH CARE

The methods used in decision analysis, such as decision trees, Bayesian analysis, and spread sheets will be discussed. Calculation of expected utilities, sensitivity analysis, assessment of patient values and inclusion of quality-of-life parameters will be discussed. *This course is designed for individuals with little experience with decision analytic methods.*

8.00 - 12.00

#### META-ANALYSIS AND OTHER STATISTICAL METHODS

Analytical methods to assess the quality of evidence for health care interventions will be discussed. Statistical approach to pooling results from several studies and application of meta-analysis in pharmacoeconomics studies and health care decision-making will be presented. *This course is designed for individuals with little experience with meta-analysis.*

8.00 - 12.00

#### QUALITY-OF-LIFE INSTRUMENTS

Health outcomes measurement instruments (conceptual and measurement models, reliability, validity, responsiveness, interpretability, respondent and administrative burden, alternate forms and cultural and language adaptation) will be discussed. *This course is designed for individuals with little experience with quality-of-life instruments.*

### TRANSLATION

Translation from English to German will be available on Friday, December 11, 1998 and Saturday, December 12, 1998 during the Plenary Sessions and General Sessions.

### MEETING PROGRAM WARNING

Please be advised that recording, by any means, of the conference presentations is prohibited. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without the express written approval from ISPOR.

---

# Inaugural *European* Conference

## CONFERENCE CO-CHAIRS

Jonathan Cooke MPharm, PhD

Peter G. Davey MD, FRCP

Alan L. Hillman MD, MBA

Karl W. Lauterbach MD, ScD

South Manchester University Hospitals, Manchester, UK

MEMO, University of Dundee, Dundee, Scotland

University of Pennsylvania, School of Medicine, Philadelphia, PA, USA

Institute for Health Economics at the University of Cologne,  
Cologne, Germany

## PROGRAM SUPPORT COMMITTEE

### COMMITTEE MEMBER

Diana Brixner RPh, PhD

Jeremy Chancellor MSc

Robert DeMarinis PhD

Lisa Egbuonu-Davis MD, MPH

Jean Paul Gagnon PhD

Bernard Genesté PhD

Kim Gilchrist MD, MBA

Anke-Peggy Holtorf PhD

Muriel Haim-Nemerson MD, PhD

Gregory P Hess MD, MBA

Joseph Jackson PhD

Kenneth E. Johnson PharmD

Koen Torfs MSc

Frances MacDonald PhD

Oliver Mast MSc

Phillip W. Sarocco

Pierre-Phillippe Sagnier

Francois Schubert PharmD, MHA, MPH

Peter Koch PhD

### INSTITUTION

Novartis Pharmaceuticals, East Hanover, NJ, USA

G.D. Searle & Company, High Wycombe, UK

Wyeth-Ayerst Research, Radnor, PA, USA

Pfizer Pharmaceutical Group, New York, NY, USA

Hoechst Marion Roussel, Kansas City, MO, USA

Rhône-Poulenc Rorer, Antony Cedex, Rhône, France

DuPont Pharmaceuticals Company, Wilmington, DE, USA

International Disease Management, Novartis, Basel, Switzerland

Merck & Company, Whitehouse Station, NJ, USA

SmithKline Beecham, Collegeville, PA, USA

Bristol-Myers Squibb, Princeton, NJ, USA

G.D. Searle & Company, Skokie, IL, USA

Janssen Pharmaceutica,

Beerse, Belgium

F. Hoffmann-LaRoche, AG,

Basel, Switzerland

Bayer AG, Leverkusen, Germany

Parke-Davis, Morris Plains, NJ, USA

Bayer AG, Leverkusen, Germany

Glaxo Wellcome plc, Uxbridge,

England

Boehringer Ingelheim GmbH,

Ingelheim, Germany



---

# Inaugural *European* Conference

DECEMBER 10, 11 & 12, 1998

RENAISSANCE KÖLN HOTEL, COLOGNE, GERMANY

Thursday, December 10, 1998

## 13.00 - 15.15 INVITED WORKSHOP

**Presenting Pharmacoeconomic Information to European Policy Makers-Case Reports**

### 13.00 - 13.15 INTRODUCTION AND CONFERENCE OBJECTIVES – DAY ONE

Peter Davey MD, FRCP, MEMO, University of Dundee, Dundee, Scotland

### 13.15 - 14.00 PRESENTING PHARMACOECONOMIC INFORMATION TO HEALTH CARE POLICY MAKERS IN THE UK - CASE REPORTS

presented by: Peter Davey MD, FRCP, MEMO, University of Dundee, Dundee, Scotland

### 14.00 - 14.45 PRESENTING PHARMACOECONOMIC INFORMATION TO THE GERMAN SICK FUND DECISION MAKERS - CASE REPORTS

presented by: Karl W. Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Cologne, Germany

### 14.45 - 15.15 QUESTIONS AND ANSWERS

## 13.00 - 15.15 CONTRIBUTED PODIUM PRESENTATIONS – ORIGINAL RESEARCH

**Outcomes Research Issues and Economic and Outcomes Study Results for Cancer**

### 13.00 - 13.15 INTRODUCTION AND CONFERENCE OBJECTIVES – DAY ONE

Karl W. Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Cologne, Germany,  
*Conference Co-chair*

### 14.15 - 14.35 J1 IDENTIFYING INITIAL DIAGNOSIS IN DATABASE RESEARCH

Lalla DV, Kozma CM, University of South Carolina, Columbia, SC, USA

### 14.35 – 14.55 J2 REVIEW OF LEGISLATION RELATING TO PROMOTION OF MEDICINAL PRODUCTS IN THE EUROPEAN UNION - IS HEALTH ECONOMICS DATA COVERED?

Duthie T<sup>1</sup>, Thomander L<sup>1</sup>, Towse A<sup>2</sup>, Kotsanos J<sup>1</sup>, Tilson H<sup>3</sup>, <sup>1</sup>Eli Lilly & Company, Basingstoke, England; <sup>2</sup>Office of Health Economics, London, England; <sup>3</sup>University of North Carolina, Chapel Hill, NC, USA

### 14.55 – 15.55 J3 HOW DOES PATIENT'S MAKE SATISFACTION JUDGMENTS? ANSWERS FROM STRUCTURAL EQUATION MODELING

Trudeau E, Mapi Values, Lyon, France

### 13.15 - 13.35 CAN1 COST-EFFECTIVENESS ANALYSIS OF HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY TREATMENT FOR METASTATIC BREAST CANCER

Trippoli S, Messori A, Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy

### 13.35 - 13.55 CAN2 A NEW METHOD FOR EXPRESSING SURVIVAL AND LIFE EXPECTANCY IN CANCER PATIENTS

Messori A, Trippoli S. Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy

### 13.55 - 14.15 CAN3 PRACTICE PATTERNS OF CHEMOTHERAPY USAGE AND ASSOCIATED NEUTROPENIA AND FEBRILE NEUTROPENIA (FN) IN EUROPE

Lyman GH, London School of Hygiene and Tropical Medicine, London, UK; H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA

## 13.00 - 15.15 CONTRIBUTED PODIUM PRESENTATIONS – ORIGINAL RESEARCH

**Economic and Outcomes Study Results for Neurologic and Gastric Disorders**

### 13.00 - 13.15 INTRODUCTION AND CONFERENCE OBJECTIVES – DAY ONE

Jonathan Cooke, MPharm, PhD, South Manchester University Hospitals, Manchester, UK, ISPOR  
*Conference Co-chair*

- 13.15 - 13.35 ND1 **AN ELEVEN YEAR, CONTROLLED STUDY OF HEALTHCARE RESOURCE USE AND MORTALITY FOR PATIENTS WITH PARKINSON'S DISEASE**  
Donnan P, Stubbings C, Steinke D, MacDonald T, McDevitt D, Morris A, Davey P, Medicines Monitoring Unit, Ninewells Hospital, Dundee, Scotland
- 13.35 - 13.55 ND2 **IMPACT OF A COST SHARING DRUG INSURANCE PLAN ON DRUG UTILIZATION AMONG INDIVIDUALS RECEIVING SOCIAL ASSISTANCE**  
Blais L, Couture J, Rahme E, LeLorier J, Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada
- 13.55 - 14.15 ND3 **ECONOMIC EVALUATION OF ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS**  
Annemans, L, Vanoverbeke, N, HEDM, Mechelen, Belgium
- 14.15 - 14.35 ND4 **CROSS-CULTURAL ADAPTATION OF THE MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ) IN 14 LANGUAGES**  
Conway K<sup>1</sup>, Uzun V<sup>1</sup>, Jhingran P<sup>2</sup>, Kwong J<sup>2</sup>, Duthie T<sup>3</sup>, <sup>1</sup>Mapi Research Institute, Lyon, France, <sup>2</sup>Glaxo Wellcome Inc, Research Triangle Park, NC, USA; <sup>3</sup>Formerly of Glaxo Wellcome, Uxbridge, UK
- 14.35 - 14.55 G11 **RATE OF GASTROPROTECTIVE AGENTS USE, DIAGNOSTIC TESTS, AND HOSPITALIZATIONS AMONG ELDERLY PATIENTS WHO STARTED ARTHROTEC, A FIXED COMBINATION OF MISOPROSTOL AND DICLOFENAC**  
Rahme E<sup>1</sup>, Joseph L<sup>2</sup>, Kong SX<sup>3</sup>, Watson DJ<sup>3</sup>, LeLorier J, <sup>1</sup>Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada, <sup>2</sup>Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada <sup>3</sup>Merck & Co., Inc., Whitehouse Station, NJ, USA
- 14.55 - 15.15 G12 **DIGEST INTERNATIONAL SURVEY: IMPACT OF UPPER GASTROINTESTINAL SYMPTOMS ON RESOURCE UTILIZATION AND QUALITY OF LIFE**  
Einarson TR, University of Toronto, Toronto, Canada, and the DIGEST Investigators

## 13.00 - 15.15 CONTRIBUTED PODIUM PRESENTATIONS – ORIGINAL RESEARCH

### Economic and Outcomes Study Results for Pulmonary Disorders & Infectious Disease

- 13.00 - 13.15 INTRODUCTION AND CONFERENCE OBJECTIVES – DAY ONE  
Thomas Kurscheid MD, MPH, Institute for Health Economics at the University of Cologne, Cologne, Germany
- 13.15 - 13.35 L1 **COMPLIANCE WITH INHALED CORTICOSTEROIDS AND HOSPITALISATION FOR ASTHMA**  
McMahon A<sup>1</sup>, Lipworth B<sup>2</sup>, Morris A<sup>1</sup>, Davey P<sup>1</sup>, MacDonald T<sup>1</sup>; <sup>1</sup>Medicines Monitoring Unit (MEMO), <sup>2</sup>Department of Clinical Pharmacology, Ninewells Hospital, Dundee, Scotland
- 13.35 - 13.55 L2 **EFFECTIVENESS OF ORAL CIPROFLOXACIN IN THE TREATMENT OF EXACERBATIONS OF CHRONIC AIRWAY DISEASES**  
Blais L<sup>1</sup>, Couture J<sup>1</sup>, Bourbeau J<sup>2</sup>, Le Lorier J<sup>1</sup>, <sup>1</sup>Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada. <sup>2</sup>Unité d'épidémiologie respiratoire, Université McGill, Montreal, Canada
- 13.55 - 14.15 L3 **QUALITY OF LIFE OF ASTHMA PATIENTS RELATIVE TO ASTHMA SEVERITY**  
Greiner W, Schulenburg Graf vd JM, Center for Health Economics and Health System Research, University of Hannover, Germany
- 14.15 - 14.35 L4 **CROSS-CULTURAL ADAPTATION OF THE PEDIATRIC ASTHMA CAREGIVER QUALITY OF LIFE QUESTIONNAIRE (PACQLQ) IN 19 COUNTRIES**  
Mear I<sup>1</sup>, Conway K<sup>1</sup>, Juniper EF<sup>2</sup>, Santanello N<sup>3</sup>; <sup>1</sup>Mapi Research Institute, Lyon, France; <sup>2</sup>McMaster University, Hamilton, Ontario, Canada; <sup>3</sup>Merck & Co Inc, Blue Bell, PA, USA
- 14.35 - 14.55 ID1 **IS TRIMETHOPRIM RESISTANCE AN OUTCOME OF COMMUNITY ANTIBIOTIC PRESCRIBING?**  
Steinke D<sup>1</sup>, Seaton R<sup>2</sup>, Phillips G<sup>3</sup>, MacDonald T<sup>1</sup>, Davey P<sup>1</sup>, <sup>1</sup>Medicines Monitoring Unit (MEMO); <sup>2</sup>Departments of Infectious Diseases; <sup>3</sup>Medical Microbiology, Ninewells Hospital, Dundee, Scotland
- 14.55 - 15.15 ID2 **CIPROFLOXACIN IS MORE SUCCESSFUL AND COST-EFFECTIVE THAN TRIMETHOPRIM/SULFAMETHOXAZOLE IN THE ORAL AMBULATORY TREATMENT OF WOMEN WITH UNCOMPLICATED ACUTE PYELONEPHRITIS**  
LeLorier J, Benhaddad A, LeLorier Y, Castilloux A-M, Desgagné A, Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada

## 15.15 –15.30 REFRESHMENT BREAK

## CONTRIBUTED WORKSHOPS

### CONTRIBUTED WORKSHOPS ARE GIVEN ON:

Session 1: Thursday 15.30-16.30 and repeated at 16.30-17.30

Session 2: Saturday, 8.30-9.30 and repeated at 9.30-10.30

Session 3: Saturday, 13.00-14.00 and repeated at 14.00-15.00

### THE CONTRIBUTED WORKSHOP TOPICS ARE:

Track 1 – Decision Support Systems & Models

Track 2 – Guidelines and Standards

Track 3 – Quality of Life Assessment

Track 4 – Study Methods

## 15.30 – 16.30 CONTRIBUTED WORKSHOPS – SESSION 1

### TRACK 1: DECISION SUPPORT SYSTEMS & MODELS

#### W5 A NATURAL HISTORY OF ALZHEIMER'S DISEASE: PATH-DEPENDENT EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES USING DECISION DATABASE METHODOLOGY

Arcelus A<sup>1</sup>, Bhattacharjya A<sup>2</sup>, Longo AE<sup>1</sup>, Kosik KS<sup>3</sup>, Finkelstein SN<sup>4</sup>, <sup>1</sup>Analysis Group/Economics, Cambridge, MA, USA; <sup>2</sup>Janssen Research Foundation, Titusville, NJ, USA; <sup>3</sup>Harvard Medical School, Boston, MA, USA; <sup>4</sup>Massachusetts Institute of Technology, Cambridge, MA, USA

### TRACK 2: GUIDELINES AND STANDARDS

#### W8 THE DEVELOPMENT AND IMPLEMENTATION OF FORMULARY SUBMISSION GUIDELINES FOR MANAGED CARE IN THE UNITED STATES

Langley P, Program in Pharmaceutical Economics and Health Systems Research, University of Colorado Health Sciences Center, Denver, CO, USA

### TRACK 3: QUALITY OF LIFE ASSESSMENT

#### W1 THE DARTS DIABETES DATABASE: HOW CAN QUALITY OF LIFE MEASUREMENTS FOR OUTCOMES RESEARCH BE INCORPORATED?

Evans JMM, Ruta DA, Davey PG, Morris AD, The DARTS / MEMO Collaboration, University of Dundee, Dundee, Scotland

#### W10 PRO AND CON OF USE DATA OF FOREIGN PHARMACOECONOMIC INVESTIGATIONS IN RUSSIA

Stratchounski L, Rozenson O. Smolensk State Medical Academy, Smolensk, Russia

### TRACK 4: STUDY METHODS

#### W15 SELF-REPORTED RESOURCE UTILIZATION DATA IN PHARMACOECONOMIC TRIALS: THEIR USE AND IMPACT ON STUDY VALIDITY

Crawford B<sup>1</sup>, Evans C<sup>2</sup>, <sup>1</sup>MAPI Values, Boston, MA, USA; <sup>2</sup>Astra Pharmaceuticals, Westborough, MA, USA

#### W16 PILOT PROJECTS IN DISEASE MANAGEMENT IN THE EASTERN EUROPE; CHALLENGES AND LESSONS LEARNED; CASE STUDY OF THE PILOT PROJECT IN THE CZECH REPUBLIC

Dittrich I<sup>1</sup>, Jirsa J<sup>2</sup>, <sup>1</sup>Prague, Czech Republic; <sup>2</sup>Via Nova s.r.o.hospital/clinic, Zabrch, Czech Republic

## 16.30 – 17.30 CONTRIBUTED WORKSHOP – SESSION 1R (SESSION 1 WORKSHOPS ARE REPEATED)

### TRACK 1: DECISION SUPPORT SYSTEMS & MODELS

#### W5 A NATURAL HISTORY OF ALZHEIMER'S DISEASE: PATH-DEPENDENT EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES USING DECISION DATABASE METHODOLOGY

Arcelus A<sup>1</sup>, Bhattacharjya A<sup>2</sup>, Longo AE<sup>1</sup>, Kosik KS<sup>3</sup>, Finkelstein SN<sup>4</sup>, <sup>1</sup>Analysis Group/Economics, Cambridge, MA, USA; <sup>2</sup>Janssen Research Foundation, Titusville, NJ, USA; <sup>3</sup>Harvard Medical School, Boston, MA, USA; <sup>4</sup>Massachusetts Institute of Technology, Cambridge, MA, USA

### TRACK 2: GUIDELINES AND STANDARDS

#### W8 THE DEVELOPMENT AND IMPLEMENTATION OF FORMULARY SUBMISSION GUIDELINES FOR MANAGED CARE IN THE UNITED STATES

Langley P, Program in Pharmaceutical Economics and Health Systems Research, University of Colorado Health Sciences Center, Denver, CO, USA

### TRACK 3: QUALITY OF LIFE ASSESSMENT

- W1 THE DARTS DIABETES DATABASE: HOW CAN QUALITY OF LIFE MEASUREMENTS FOR OUTCOMES RESEARCH BE INCORPORATED?**  
Evans JMM, Ruta DA, Davey PG, Morris AD, The DARTS / MEMO Collaboration, University of Dundee, Dundee, Scotland
- W10 PRO AND CON OF USE DATA OF FOREIGN PHARMACOECONOMIC INVESTIGATIONS IN RUSSIA**  
Stratchounski L, Rozenson O. Smolensk State Medical Academy, Smolensk, Russia

### TRACK 4: STUDY METHODS

- W15 SELF-REPORTED RESOURCE UTILIZATION DATA IN PHARMACOECONOMIC TRIALS: THEIR USE AND IMPACT ON STUDY VALIDITY**  
Crawford B<sup>1</sup>, Evans C<sup>2</sup>, <sup>1</sup>MAPI Values, Boston, MA, USA; <sup>2</sup>Astra Pharmaceuticals, Westborough, MA, USA
- W16 PILOT PROJECTS IN DISEASE MANAGEMENT IN THE EASTERN EUROPE; CHALLENGES AND LESSONS LEARNED; CASE STUDY OF THE PILOT PROJECT IN THE CZECH REPUBLIC**  
Dittrich I<sup>1</sup>, Jirsa J<sup>2</sup>, <sup>1</sup>Prague, Czech Republic; <sup>2</sup>Via Nova s.r.o.hospital/clinic, Zabrach, Czech Republic

## 17.30 – 19.00 WINE & CHEESE RECEPTION & VIEWING OF CONTRIBUTED POSTERS PRESENTATION-SESSION 1

### Contributed Poster Presentations

#### CANCER AND AIDS

- PCA1 PHARMACOECONOMIC EFFICIENCY OF THE USE OF PROTEASE-INHIBITORS FOR HOSPITAL IN PATIENTS WITH AIDS**  
Rahmouni S, Peyron F, Flori A, Moreau J, Charbitt JJ, Bués-Charbit M, Balanard G, North Hospital, Marseilles, France
- PCA2 THE COST-EFFECTIVENESS OF ITRACONAZOLE SOLUTION IN THE TREATMENT OF ORAL CANDIDIASIS IN HIV/AIDS PATIENTS: AN INTERNATIONAL COMPARISON**  
McGann ME<sup>1</sup>, Halpern M<sup>1</sup>, Rance L<sup>2</sup>, Ajax MJ<sup>1</sup>, <sup>1</sup>MEDTAP International, Seattle, Washington, USA; <sup>2</sup>Janssen-Ortho, Inc, North York, Ontario, Canada
- PCA3 ECONOMIC CONSEQUENCES OF MONOCLONAL ANTIBODY 17-1A ADJUVANT THERAPY OF RESECTED DUKES' C COLORECTAL CARCINOMA IN GERMANY**  
Schädlich PK<sup>1</sup>, Lützelberger U<sup>2</sup>, Brecht JG<sup>1</sup>, Volmer T<sup>2</sup>, <sup>1</sup>InForMed GmbH, Hamburg, Germany; <sup>2</sup>Glaxo Wellcome GmbH, Hamburg, Germany
- PCA4 OUTCOME OF MONOCLONAL ANTIBODY 17-1A ADJUVANT THERAPY OF RESECTED COLON CANCER DUKES' C IN GERMANY: A SUB-GROUP ANALYSIS**  
Brecht JG<sup>1</sup>, Volmer T<sup>2</sup>, Schädlich PK<sup>1</sup>, Lützelberger U<sup>2</sup>, <sup>1</sup>InForMed, GmbH, Hamburg, Germany; <sup>2</sup>Glaxo Wellcome GmbH, Hamburg, Germany
- PCA5 QUALITY OF LIFE IN HODGKIN'S DISEASE RESULTS FROM THE EORTC AND GHSG TRIALS**  
Fletcher H<sup>1</sup>, Rufer JU<sup>2</sup>, <sup>1</sup>Clinic for Child and Adolescent Psychiatry; <sup>2</sup>Medical Department I, University of Cologne, Cologne, Germany
- PCA6 COST-EFFECTIVENESS OF GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER**  
Trippoli S, Messori A, Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy
- PCA7 COST ESTIMATION OF SEVERE NEUTROPENIA IN BELGIUM**  
Annemans L<sup>1</sup>, Eynatten C<sup>1</sup>, De Smedt B<sup>2</sup>, Alwan A<sup>3</sup>, Vanschoubroek K<sup>4</sup>, Standaert B<sup>4</sup> <sup>1</sup>HEDM, Mechelen, Belgium; <sup>2</sup>BDS Clinical Services, Mechelen, Belgium; <sup>3</sup>MEDSTAT, Antwerp, Belgium; <sup>4</sup>Amgen, Brussels, Belgium
- PCA8 COST MINIMIZATION IN THE USE OF THE COLONY-STIMULATING FACTORS (CSFS) BASED ON CLINICAL PREDICTION MODELS (CPMS)**  
Lyman GH<sup>1,2</sup>, Kuderer NM<sup>3</sup>, Balducci L<sup>2</sup>, <sup>1</sup>London School of Hygiene and Tropical Medicine, London, UK; <sup>2</sup>H Lee Moffitt Cancer Center and Research Center, Tampa, FL, USA; <sup>3</sup>Albert-Ludwigs-Universität, Freiburg, Germany
- PCA9 QUALITY OF LIFE (QOL) OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA (LG-NHL) TREATED WITH FLUDARABINE (F) OR CYCLOPHOSPHAMIDE-VINCRIStINE- PREDNISONE (CVP)**  
Bérubé S<sup>1</sup>, Meyer R<sup>2</sup>, Klasa R<sup>3</sup>, Shustik C<sup>4</sup>, <sup>1</sup>Berlex Canada Inc, Quebec, Canada; <sup>2</sup>Hamilton Regional Cancer Centre, Hamilton, Canada; <sup>3</sup>BC Cancer Agency, Vancouver, Canada; <sup>4</sup>McGill Oncology Group, Montreal, Canada

**PCA10 THE RELATIONSHIP BETWEEN PROFILE-BASED QUALITY OF LIFE SCORES AND EUROQOL-5D SCORES IN BREAST CANCER SURGERY PATIENTS**

Namjoshi M, Taylor T, Hohl R, The University of Iowa, Iowa City, USA

**CARDIOVASCULAR DISEASE**

**PCV1 COST-EFFECTIVENESS OF LIPID MODULATOR AGENTS**

Lacour A, Derderian F, LeLorier J, Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada

**PCV2 ADAPTING ECONOMIC ANALYSES FROM ONE COUNTRY TO ANOTHER: DO THE WOSCOPS UK FINDINGS HOLD IN BELGIUM?**

Caro JJ, Huybrechts KF for the WOSCOPS Study Group, Caro Research, Boston, MA, USA

**PCV3 EFFICACY OF CARDIAC REHABILITATION THERAPY: A PROSPECTIVE MULTICENTER COHORT STUDY**

Willich SN, Völler H, Binting S, Gohlke H, Hahmann H, Kleber F, Klein G, Krobot K, Bestehorn K for the PIN Study Group, Institute for Social Medicine and Epidemiology, Charité University Hospital, Humboldt University of Berlin, Berlin, Germany

**PCV4 THE ECONOMIC IMPACT OF HYPERTENSION STUDY FROM THE PISTOIA PROJECT**

Potenza A<sup>1</sup>, Berto P<sup>2</sup>, Feroci P<sup>1</sup>, Lattari P<sup>1</sup>, Pacini R<sup>1</sup>, Mundula V<sup>1</sup>, Papini D<sup>3</sup>, Reggion S<sup>4</sup> ASL<sup>3</sup>, Pistoia, Italy; <sup>2</sup>Pbe consultants, Verona, Italy; <sup>3</sup> School of Medicine, Firenze, Italy; <sup>4</sup> Pfizer Italiana, Roma, Italy

**PCV5 POTENTIAL COST SAVINGS OF THE 4 FRENCH INFINITI CATHETER IN DIAGNOSTIC CORONARY ANGIOGRAPHY**

Neighbors D<sup>1</sup>, Buckingham T<sup>1</sup>, Greiner W<sup>2</sup>, Schulenburg J<sup>2</sup>, <sup>1</sup>Center for Economics Research, Research Triangle Institute, Research Triangle Park, NC, USA; <sup>2</sup>Centre for Health Economics and Health System Research, University of Hannover, Hannover, Germany

**PCV6 MEASURING DISEASE-SPECIFIC SYMPTOM IMPACT: DEVELOPMENT OF THE ATRIAL FIBRILLATION IMPACT SCALE (AFIS)**

Turner R, Kocal M, Testa M, <sup>1</sup>PHASE V Technologies Inc, Wellesley Hills, MA, USA, Harvard School of Public Health, Boston, MA, USA

**PCV7 CROSS-CULTURAL ADAPTATION OF THE SEATTLE ANGINA QUESTIONNAIRE (SAQ) IN 11 COUNTRIES**

Conway K<sup>1</sup>, Uzun V<sup>1</sup>, Spertus J<sup>2</sup>, Fletcher A<sup>3</sup>, Sagnier P<sup>4</sup>, <sup>1</sup>Mapi Research Institute, Lyon, France, <sup>2</sup>University of Missouri, Kansas City, USA, <sup>3</sup>London School of Hygiene and Tropical Medicine, London, UK, <sup>4</sup>Bayer AG, Pharma Europe, Leverkusen, Germany

**PCV8 PRELIMINARY QUALITY OF LIFE EVALUATION OF THE GERMAN S.A.T.-TRIAL : COMPARISON OF SF-36, EUROQOL, TIME-TRADE-OFF METHOD AND WILLINGNESS-TO-PAY**

Hunsche E, Kurscheid T, Wendland G, Lauterbach K. W, Institute for Health Economics at the University of Cologne, Cologne, Germany

**GASTROINTESTINAL AND URINARY TRACT DISORDERS**

**PGIU1 WILLINGNESS TO PAY OF PATIENTS WITH PAINFUL-IRRITABLE BLADDER SYNDROME**

Budhiarso I<sup>1</sup>, Bushnell D<sup>1</sup>, Ramsey S<sup>2</sup>, <sup>1</sup>Health Research Associates, Inc., Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA

**PGIU2 EVALUATING CLINICAL OUTCOMES OF GERD TREATMENT OPTIONS USING DECISION ANALYSIS**

McGhan WF<sup>1</sup>, Smith MD<sup>2</sup>, Crawley JA<sup>3</sup>, <sup>1</sup>University of the Sciences at Philadelphia, Philadelphia, PA USA, <sup>2</sup>Health Decision Strategies, Princeton, NJ, USA, <sup>3</sup>Astra Pharmaceuticals, Wayne, PA, USA

**PGIU3 THE EFFECTS OF ULCER-HEALING DRUG COPRESCRIPTION ON NSAID INDUCED GASTROINTESTINAL EVENTS: A RECORD LINKAGE COHORT STUDY**

Morant SV<sup>1,2</sup>, Shield MJ<sup>2</sup>, MacDonald TM<sup>1</sup>, <sup>1</sup>Medicines Monitoring Unit, University of Dundee, Dundee, Scotland; <sup>2</sup>Searle, High Wycombe, UK

**PGIU4 CROSS-CULTURAL ADAPTATION OF THE PATIENT ASSESSMENT OF CONSTIPATION-SYMPTOM QUESTIONNAIRE (PAC-SYM)**

Conway K<sup>1</sup>, Uzun V<sup>1</sup>, Frank L<sup>2</sup>, Marquis P<sup>3</sup>, Farup C<sup>4</sup>, Dubois D<sup>5</sup>, <sup>1</sup>Mapi Research Institute, Lyon, France, <sup>2</sup>MEDTAP International Inc., Bethesda, MD, USA, <sup>3</sup>Mapi Values, Lyon, France, <sup>4</sup>Janssen Research Foundation, Titusville, NJ, USA, <sup>5</sup>Janssen Research Foundation, Beerse, Belgium

**PGIU5 COST-UTILITY-ANALYSIS OF LAPAROSCOPIC VERSUS OPEN SURGERY FOR COLONIC DISEASE**

Eypasch E, Köhler L, Tschubar F, Troidl H, Lauterbach K, St Hildegardis Hospital, II, Department of Surgery, University of Cologne, Cologne, Germany and Institute of Health Economics at the University of Cologne, Cologne, Germany

## DIABETES

- PD1 COMPLIANCE WITH AMERICAN DIABETIC ASSOCIATION (ADA) RECOMMENDATIONS IN A TYPE 2 DIABETIC POPULATION IN AN ACADEMIC FAMILY MEDICINE CENTER**  
Longe RL<sup>1</sup>, Taylor AT<sup>1</sup>, Wagner PJ<sup>2</sup>, <sup>1</sup>University of Georgia, Athens, GA, USA; <sup>2</sup>Medical College of Georgia, Augusta, GA, USA
- PD2 THE CULTURAL VALIDATION OF THE DIABETIC FOOT ULCER SCALE: METHODS AND ISSUES**  
Conway K<sup>1</sup>, Pouget C<sup>1</sup>, Finn P<sup>2</sup>, Abetz L<sup>3</sup>, and McNulty P<sup>2</sup>, <sup>1</sup>Mapi Research Institute, France, <sup>2</sup>Johnson & Johnson, USA, <sup>3</sup>Mapi Values, UK
- PD3 A NEW QUALITY MANAGEMENT SYSTEM IN NEPHROLOGY (QUALITÄTSMANAGEMENTSYSTEM-NIERE – QMS-N)**  
M. Schulz<sup>1</sup>, H. Rosenberg<sup>2</sup>, K. W. Lauterbach<sup>2</sup>, C. A. Baldamus<sup>1</sup>, <sup>1</sup>Medicine Clinic IV at the University of Cologne, Cologne, Germany, <sup>2</sup>Institute for Health Economics at the University of Cologne, Cologne, Germany

## Friday, December 11, 1998

### 8.30 - 8.45 INTRODUCTIONS AND CONFERENCE OBJECTIVES – DAY 2

Peter G. Davey MD, FRCP, MEMO, University of Dundee, *ISPOR Conference Co-chair*

Karl Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, *Conference Co-chair*

Jonathan Cooke MPharm, PhD, South Manchester University Hospitals, *ISPOR Conference Co-chair*

Alan L. Hillman MD, MBA, University of Pennsylvania, *ISPOR Conference Co-chair*

### 8.45 - 10.15 PLENARY SESSION

#### 8.45 - 9.30 What Is the Current Use and Future Trends for Pharmacoeconomic and Outcomes Information in European Countries

presented by: Michael Drummond PhD, Professor, Centre for Health Economics, University of York

#### 9.30 - 10.15 World Health Organization (WHO) Health Policy Concept in Europe

presented by: Herbert F.K. Zöllner PhD, Regional Adviser, WHO Health Economics and Policy Analysis, Copenhagen, Denmark

### 10.15 - 10.30 BREAK

### 10.30 -12.30 FIRST GENERAL SESSION

#### Developing Consensus on Pharmacoeconomic Methodology

Moderator: Peter Davey MD, FRCP, MEMO, University of Dundee, Dundee, Scotland

##### REPORT FROM THE ISPOR US CONSENSUS DEVELOPMENT ADVISORY PANELS ON THE STANDARDIZATION OF PHARMACOECONOMIC METHODOLOGY

Speaker: Joel W. Hay PhD, University of Southern California, College of Pharmacy, Los Angeles, CA, USA

##### DEVELOPING CONSENSUS ON PHARMACOECONOMIC METHODOLOGY-COMPARING AND CONTRASTING THE HARMET AND OTHER INITIATIVES IN EUROPE TO THE US INITIATIVE - STRENGTHS AND WEAKNESSES

Speakers: The European Panel

- Werner Brouwer MD, The Netherlands
- Jonathan Cooke MPharm, PhD, MPharm, South Manchester University Hospitals, Manchester, UK
- Michael Drummond PhD, University of York, Centre for Health Economics, York, UK
- Livio Garattini MD, CESAV Centre for Health Economics, Institute for Pharmacological Research, Ranica, Italy
- Bengt G. Jönsson MA, PhD, Stockholm School of Economics, Stockholm, Sweden (invited)
- Karl W. Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Cologne, Germany
- Frank Peys PhD, Belgium Institute for Health Economics, Brussels, Belgium

- Claude Le Pen PhD, Université Paris-Dauphine, Paris, France
- Hugo Robays, University Hospital Gent, Gent, Belgium
- Joan Rovira PhD, SOIKOS, Department of Economics, University of Barcelona, Barcelona, Spain
- J.Matthias Graf von Schulenberg PhD, Centre for Health Economics and Health System-HSR, University of Hannover, Hannover, Germany

## 12.30 - 13.30 LUNCH & CONTRIBUTED POSTER PRESENTATIONS-SESSION 1

### 13.30 - 15.00 SECOND GENERAL SESSION

#### Using Evidence-Based Medicine to Deliver Cost-Effective Health Care - Focusing on Cardiovascular Disease

Moderator: Alan L. Hillman MD, MBA University of Pennsylvania, School of Medicine, Philadelphia, PA USA

##### **COST-EFFECTIVE MANAGEMENT OF HYPERTENSION**

Speaker: Hanne Thümer, Regional Hospital of Trondheim, Trondheim, Norway

##### **CONTROVERSIES WITH LIPID-LOWERING AGENTS**

Speaker: Karl Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne, Cologne, Germany

##### **WHY DON'T DOCTORS PRESCRIBE EFFECTIVE TREATMENTS FOR SECONDARY PREVENTION AFTER ACUTE MYOCARDIAL INFARCTION?**

Speaker: David Wood MD, ChB, MSc, FRCP, FESC, Imperial College School of Medicine at the National Heart and Lung Institute, Royal Brompton NHS Trust and Bromley Hospital NHS Trust, London, UK

## 15.00 - 15.30 BREAK AND VIEWING OF CONTRIBUTED POSTER PRESENTATIONS – SESSION 2

### 15.30 -17.30 CONTRIBUTED PODIUM PRESENTATIONS – ORIGINAL RESEARCH

#### Economic & Outcomes Study Results for Cardiovascular Disease

- |               |     |   |
|---------------|-----|---|
| 15.30 – 15.50 | CV1 | <b>ECONOMIC IMPACT OF THE ANTI-HYPERTENSIVE THERAPY WITH VALSARTAN</b><br>Fricke F-U, Pirk O, Novartis Pharma GmbH, Department of Health Economics, Nuremberg, Germany  |
| 15.50 – 16.10 | CV2 | <b>COST-EFFECTIVENESS OF TREATING HIGH RISK INDIVIDUALS AGE 45-65 WITH STATINS IN GERMANY FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE</b><br>Lauterbach K, Hunsche E, Klewer U, Institute of Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany                               |
| 16.10 – 16.30 | CV3 | <b>UTILIZATION OF ACE INHIBITORS IN CONGESTIVE HEART FAILURE AMONG ELDERLY IN QUEBEC</b><br>Couture J, Blais L, Castilloux A-M, LeLorier J. Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Quebec, Canada  |
| 16.30 – 16.50 | CV4 | <b>IMPROVED MYOCARDIAL PROTECTION DURING CORONARY BYPASS SURGERY SHORTENS HOSPITAL STAY AND SAVES COSTS</b><br>Mehlhorn U, Fattah M, Kuhn-Regnier F, Geissler HJ, Südkamp M, Horst M, Hekmat K, Dapunt O, de Vivie ER, Clinic for Cardiothoracic Surgery, University of Cologne, Cologne, Germany                                 |
| 16.50 – 17.10 | CV5 | <b>ECONOMIC ASSESSMENT OF A PROPHYLACTIC TREATMENT OF RECURRENCE OF ISCHEMIC ACCIDENTS BY LYSINE ACETYLSALICYLATE</b><br>Marissal JP, Selke B, Lebrun T, CRESGE, Lille, France  |
| 17.10 – 17.30 | CV6 | <b>OUTCOME OF ACUTE MYOCARDIAL INFARCTION PATIENTS WITH A MAXIMAL INDIVIDUAL THERAPIE (MITRA-STUDY)</b><br>Dommke C, Schiele R, Fischer F, Wienbergen H, Voigtländer T, Glunz HG, Berg G, Gieseler U, Lauterbach KW <sup>1</sup> , Senges J. Herzzentrum Ludwigshafen; Universität Köln, for the MITRA Study Group, Köln, Germany |

---

## 15.30 - 17.30 CONTRIBUTED PODIUM PRESENTATIONS – ORIGINAL RESEARCH

### Economic & Outcomes Study Results for Mental Health

- 15.30 – 15.50 **MH1 ROAD TRAFFIC ACCIDENTS ARE ASSOCIATED WITH BENZODIAZEPINE USE**  
Barbone F<sup>2</sup>, McMahon AD<sup>1</sup>, Davey PG<sup>1</sup>, Morris AD, McDevitt DG, MacDonald TM<sup>1</sup>, <sup>1</sup>Medicines Monitoring Unit (MEMO), University of Dundee, Ninewells Hospital & Medical School, Dundee, Scotland, <sup>2</sup>Chair of Hygiene and Epidemiology, DPMSC, University of Udine, Italy
- 15.50 – 16.10 **MH2 NEW BENZODIAZEPINE USE IS ASSOCIATED WITH AN AGE RELATED RISK OF HOSPITALISATION WITH FRACTURE AND OTHER TRAUMA: A POPULATION BASED STUDY.**  
Steinke D<sup>1</sup>, Davey P<sup>1</sup>, Elliott L<sup>2</sup>, Dowell J<sup>3</sup>, Morris A<sup>1</sup>, MacDonald T<sup>1</sup>, <sup>1</sup>Medicines Monitoring Unit; <sup>2</sup>Tayside School of Nursing & Midwifery; <sup>3</sup>Tayside Centre for General Practice, Ninewells Hospital, Dundee, Scotland
- 16.10 – 16.30 **MH3 ASSESSING THE SASKATCHEWAN DATABASE FOR OUTCOMES STUDIES OF DEPRESSION AND ITS TREATMENT**  
West S, Richter A, Nennstiel M, Mauskopf J, Research Triangle Institute, Research Triangle Park, NC, USA
- 16.30 – 16.50 **MH4 ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIOURS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY, IN FRANCE; 1. EPIDEMIOLOGY**  
Cal M-L<sup>1</sup>, Dartigues J-F<sup>2</sup>, Gérard D<sup>3</sup>, Léger J-M<sup>4</sup>, <sup>1</sup>Groupe de Recherche en Économie de la Santé, Université Victor Segalen, Bordeaux, France; <sup>2</sup>INSERM U330, Université Victor Segalen, Bordeaux, France; <sup>3</sup>Laboratoires Synthélabo, Meudon-La-Forêt, France; <sup>4</sup>Centre Hospitalier Spécialisé Esquirol, Limoges, France
- 16.50 – 17.10 **MH5 ECONOMIC IMPACT OF AGITATED AND AGGRESSIVE BEHAVIOURS OF ELDERLY INDIVIDUALS DWELLING IN THE COMMUNITY, IN FRANCE: 2. COST ANALYSIS**  
Cal M-L<sup>1</sup>, Prudhomme M-L<sup>2</sup>, <sup>1</sup>Groupe de Recherche en Économie de la Santé, Université Victor Segalen Bordeaux<sup>2</sup>, France; <sup>2</sup>Synthélabo, Meudon-La-Forêt, France
- 17.10 – 17.30 **MH6 COST-UTILITY ANALYSIS OF RISPERIDONE IN CHRONIC SCHIZOPHRENIA**  
Iskedjian M, Oh P, Einarson TR, Lanctôt K, Addis A. University of Toronto, Toronto, Canada

## 15.30 - 17.30 CONTRIBUTED PODIUM PRESENTATIONS – ORIGINAL RESEARCH

### Economic & Outcomes Study Results for Diabetes and Infectious Disease

- 15.30 – 15.50 **D1 SELF-MONITORING OF BLOOD GLUCOSE IN DIABETES: IS IT WORTH IT?**  
Evans JMM, Boyle DIR, Davey PG, Morris AD; The DARTS / MEMO Collaboration, University of Dundee, Dundee, Scotland
- 15.50 – 16.10 **D2 PATIENT-HELD INSTRUMENTS FOR RECORDING AMBULATORY CARE RESOURCE USE: EXPERIENCE IN PATIENTS WITH DIABETIC FOOT ULCERS**  
Constenla D<sup>1</sup>, Chambers M<sup>1</sup>, Sigler C<sup>2</sup>, <sup>1</sup>MEDTAP International Inc., London, UK; <sup>2</sup>Parke-Davis Pharmaceutical Research, Ann Arbor, MI, USA
- 16.10 – 16.30 **D3 ANTITHYROID DRUGS OR RADIOIODINE AS FIRST-LINE THERAPY OF GRAVES' HYPERTHYROIDISM IN A COUNTRY WITH STRICT REGULATIONS FOR RADIATION PROTECTION ?**  
Dietlein M<sup>1</sup>, Moka D<sup>1</sup>, Hunsche E<sup>2</sup>, Dederichs B<sup>1</sup>, Lauterbach KW<sup>2</sup>, Schicha H<sup>1</sup>, <sup>1</sup>Department of Nuclear Medicine; <sup>2</sup>Institute of Health Economics, University of Cologne, Cologne, Germany
- 16.30 – 16.50 **D4 MEASURING THE IMPACT OF DIABETIC FOOT ULCERS ON QUALITY OF LIFE FROM THE PATIENT'S PERSPECTIVE**  
J Ward<sup>1</sup> P McNulty<sup>2</sup>, L Abetz<sup>3</sup>, M Sutton<sup>1</sup>, and L Brady<sup>2</sup>, <sup>1</sup>Johnson & Johnson, USA; <sup>2</sup>Royal Hallamshire Hospital, Cheshire, UK, <sup>3</sup>Mapi Values, Cheshire, UK
- 16.50 – 17.10 **IM1 ASSESSING THE VALUE OF EPOETIN ALFA VS. AUTOLOGOUS BLOOD DONATION IN ORTHOPEDIC SURGERY: A FEASIBILITY STUDY OF CONTINGENT VALUATION**  
Persson U,<sup>1</sup>Martens L<sup>2</sup>, <sup>1</sup>IHE, Swedish Institute for Health Economics, Lund, Sweden; <sup>2</sup>ICOM Health Economics, Robert Wood Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
- 17.10 – 17.30 **IM2 EPOETIN ALFA REDUCES POST-OPERATIVE LENGTH OF STAY IN PATIENTS UNDERGOING KNEE REPLACEMENT**  
Gagnon D, Parasuraman B, Martens L, ICOM Health Economics, Robert Wood Johnson Pharmaceutical Research Institute, Raritan, NJ, USA

## 17.30 - 18.30 KEYNOTE SPEAKERS & COMMITTEE RECOGNITION

### Keynote speakers:

Professor Erland Erdmann MD, Prorektor of the University of Cologne

Robert S. Epstein MD, MS, Vice President, Merck-Medco Managed Care LLC, Montvale, NJ, USA and *ISPOR President*

**18.30 – 20.00 RECEPTION AND VIEWING OF CONTRIBUTED POSTER PRESENTATION-SESSION 2**

**Contributed Poster Presentations**

**INFECTIOUS DISEASE**

- PID1 COST EFFECTIVENESS OF LEVOFLOXACIN VERSUS CLARITHROMYCIN IN PATIENTS EVALUABLE FOR CLINICAL EFFICACY IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS**  
Rance L F<sup>1</sup>, Dornsief B F<sup>2</sup>, <sup>1</sup>Janssen-Ortho Inc., Toronto, Canada; <sup>2</sup>Advanced Biologics, Lambertville, NJ USA
- PID2 COST-MINIMIZATION ANALYSIS OF CEFAMANDOLE AND TOBRAMYCIN VS STANDARD THERAPY IN THE TREATMENT OF PATIENTS WITH LOCAL APPENDICULAR PERITONITIS**  
Rozenon O<sup>1</sup>, Bazganov N<sup>2</sup>, Belkov A<sup>1</sup>, Bikov A<sup>3</sup>, Stratchounski L<sup>1</sup>, <sup>1</sup>Smolensk State Medical Academy, Smolensk, Russia; <sup>2</sup>Yaroslavl'sky State Medical Academy, Yaroslavl, Russia; <sup>3</sup>Volgogradskaya State Medical Academy, Volgograd, Russia

**MENTAL HEALTH AND NEUROLOGIC DISORDERS**

- PMH1 ANNUAL DIRECT COSTS OF PSYCHOTROPIC MEDICATIONS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS IN INDIA**  
Chaturvedi, Santosh K, National Institute of Mental Health & Neurosciences, Bangalore, India
- PMH2 CLINICAL AND ECONOMIC CHARACTERIZATION OF FAMILY MEDICINE PATIENTS RECEIVING ANTIDEPRESSANT DRUGS**  
Taylor AT<sup>1</sup>, Wagner PJ<sup>2</sup>, Ahmed A<sup>1</sup>, <sup>1</sup>University of Georgia College of Pharmacy and <sup>2</sup>Medical College of Georgia School of Medicine, Athens and Augusta, GA, USA
- PMH3 COST-EFFECTIVENESS OF FLUVOXAMINE IN THE TREATMENT OF RECURRENT DEPRESSION IN FRANCE**  
Nuijten MJC<sup>1</sup>, Piercy J<sup>2</sup>, <sup>1</sup>The Lewin Group, Hoofddorp, The Netherlands; <sup>2</sup>Solvay Pharmaceuticals, Hannover, Germany
- PMH4 THE BUDGET IMPACT PHARMACOTHERAPY SELECTION FOR MAJOR DEPRESSIVE DISORDER: A MULTINATIONAL STUDY**  
Casciano, JP<sup>1</sup>, Einarson, TR<sup>3</sup>, Arikian, SA<sup>1,2</sup>, Doyle, JJ<sup>1,2</sup>, <sup>1</sup>The Analytica Group, Ltd., New York, NY, USA; <sup>2</sup>Columbia School of Public Health, New York, NY, USA; <sup>3</sup>Faculty of Pharmacy, University of Toronto, Ontario, Canada
- PMH5 COST OF CARE OF ALZHEIMER'S DISEASE IN THE UNITED KINGDOM**  
Thwaites RMA<sup>1</sup>, Yeardley HL<sup>2</sup>, <sup>1</sup>Glaxo Wellcome Research & Development, Greenford, UK; <sup>2</sup>Quintiles, Neu-Isenburg, Germany
- PMH6 DEVELOPMENT OF A NEW DISEASE-SPECIFIC QUALITY OF LIFE SCALE FOR USE IN SCHIZOPHRENIA**  
Wild D<sup>1</sup>, Jenkinson C<sup>1</sup>, Fitzpatrick, R<sup>1</sup>, Wilkinson G<sup>2</sup>, Hesdon, B<sup>2</sup>, Farina C<sup>3</sup>, <sup>1</sup>Oxford Outcomes, Institute of Health Sciences, Oxford, UK; <sup>2</sup>Department of Psychiatry, University of Liverpool, Liverpool, UK; <sup>3</sup>Janssen Cilag Ltd, Saunderton, High Wycombe, UK
- PMH7 CROSS-CULTURAL ADAPTATION OF THE INTERNATIONAL INDEX OF ERECTILE FUNCTION (IIEF) IN 31 COUNTRIES**  
Conway K<sup>1</sup>, Mishra A<sup>2</sup>, Giroudet C<sup>1</sup>, The Global Translation Group (31 QoL Experts) <sup>1</sup>Mapi Research Institute, Lyon, France; <sup>2</sup>Pfizer, Groton, CT, USA
- PN1 A UK PRIMARY CARE DATABASE (UKPCD)-UK MEDIPLUS AS A READILY AVAILABLE RESEARCH TOOL FOR DETERMINING THE INCIDENCE AND PREVALENCE OF MULTIPLE SCLEROSIS, ITS TREATMENT, PRESCRIPTION COSTS AND REFERRALS IN UK PRACTICE**  
Carmichael R, Grigas E, Harrison P, McDermott, J, Disease Treatment and Outcomes Group, IMS Health, Middlesex, England
- PN2 RESULTS OF DISEASE MANAGEMENT IN HEADACHE TREATMENT**  
Göbel H<sup>1</sup>, Behrens M<sup>2</sup>, <sup>1</sup>Neurological Clinic, University of Kiel and Neurological Pain Clinic, Kiel, Germany; <sup>2</sup>Glaxo Wellcome GmbH&Co., Hamburg, Germany
- PN3 A FOUNDATION STUDY FOR COST-EFFECTIVENESS ANALYSIS: THE DEFINITION OF ECONOMIC PARAMETERS AND CLINICAL ENDPOINTS IN PARKINSON'S DISEASE**  
Saal G<sup>1</sup>, Adesina K<sup>1</sup>, Shuster S<sup>2</sup>, <sup>1</sup>MAPI Values, Cheshire, UK; <sup>2</sup>Medtronic Neurological, Minneapolis, MN, USA
- PN4 QUALITY OF LIFE AND FUNCTIONAL STATUS MEASURES IN ADVANCED PARKINSON'S PATIENTS TREATED WITH PRAMIPEXOLE, BROMOCRIPTINE, OR PLACEBO**  
Greer M<sup>1</sup>, Guttman M<sup>2</sup>, Meier D<sup>3</sup>, Leonard J<sup>3</sup>, Koester J<sup>3</sup>; <sup>1</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; <sup>2</sup>Markham, Ontario, Canada; <sup>3</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany

**PN5 CROSS-CULTURAL ADAPTATION OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS) QUESTIONNAIRE IN 9 COUNTRIES**

Conway K<sup>1</sup>, Ojanen M<sup>1</sup>, Cella D<sup>2</sup>, Lent L<sup>2</sup>, Eremenco S<sup>2</sup>, Sagnier P<sup>3</sup>, <sup>1</sup>Mapi Research Institute, Lyon, France; <sup>2</sup>Center on Outcomes, Research and Education, Evanston, IL, USA; <sup>3</sup>Bayer AG, Pharma Europe, Leverkusen, Germany

**PULMONARY AND ARTHRITIC DISORDERS**

**PP1 CHARACTERISTICS OF CHRONIC AIRWAY DISEASE PATIENTS STARTED ON NEBULIZED IPRATROPIUM SOLUTION**

Blais L<sup>1</sup>, Castilloux A-M<sup>1</sup>, Renzi P<sup>1</sup>, LeLorier J<sup>1</sup>, Miller B<sup>2</sup>. <sup>1</sup>Centre de recherche, Centre hospitalier de l'Université de Montréal, Campus Hôtel-Dieu, Canada, <sup>2</sup>Boehringer Ingelheim Ltd, Burlington, Ontario, Canada

**PP2 THE EFFECT OF AGE ON COST-EFFECTIVENESS IN THE TREATMENT OF MODERATE ASTHMA**

Kielhorn, A, Behrens, M, Glaxo Wellcome GmbH&Co, Hamburg, Germany

**PP3 INCREMENTAL COST OF DISEASE IN NOSOCOMIAL PNEUMONIA FROM A HOSPITAL'S PERSPECTIVE - A FEASIBILITY STUDY**

Dietrich ES<sup>1</sup>, Hug S<sup>1</sup>, Mast O<sup>2</sup>, Schulgen G<sup>3</sup>, Daschner F<sup>1</sup>, <sup>1</sup>Institute of Environmental Medicine and Hospital Epidemiology, University Hospital, Freiburg, Germany; <sup>2</sup>Health Economics and Outcomes Research, Bayer Vital, Leverkusen, Germany; <sup>3</sup>Institute of Biometry and Medical Informatics, University Hospital, Freiburg, Germany

**PP4 ECONOMIC IMPACT OF SMOKING IN GERMANY**

Ruff L<sup>1</sup>, Meyer A<sup>1</sup>, Volmer T<sup>2</sup>, Nowak D<sup>3</sup> <sup>1</sup>Medizinische Klinik, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany; <sup>2</sup>Glaxo Wellcome, Hamburg, Germany; <sup>3</sup>Institut und Poliklinik für Arbeits- und Umweltmedizin, Ludwig Maximilians-Universität, München, Germany

**PIM1 COST-EFFECTIVENESS ANALYSIS OF A FIXED COMBINATION DICLOFENAC+MISOPROSTOL IN THE PREVENTION OF GASTROPATHY IN ARTHRITIS PATIENTS IN BELGIUM**

Annemans L, Vanoverbeke N, Van Rompay W, HEDM, Mechelen, Belgium

**PIM2 COST OF ILLNESS IN EARLY RHEUMATOID ARTHRITIS STRATIFIED FOR SOCIAL STATUS**

Merkesdal S, Ruof J, Mau W, Zeidler H, Department of Rheumatology, Medical School of Hannover, Hannover, Germany

**PIM3 QUALITY OF LIFE SCORES AS PREDICTORS OF FUTURE HEALTHCARE RESOURCE USE IN PATIENTS WITH ARTHRITIS**

Wolfe F<sup>1</sup>, Kahler K<sup>2</sup>, Kong SX<sup>2</sup>, <sup>1</sup>Arthritis Research Center, University of Kansas, Wichita, KS, USA; <sup>2</sup>Merck & Co., Inc., Whitehouse Station, NJ, USA

**PHARMACOECONOMIC METHODS AND COST OF CARE**

**PMC1 MEDICATION COMPLIANCE AND EXPENDITURE IMPACT ASSOCIATED WITH PHARMACIST'S COGNITIVE SERVICE INTERVENTIONS**

Smith D<sup>1,2</sup>, Stergachis A<sup>1</sup>, Christensen D<sup>1,3</sup>, Sullivan S<sup>1</sup>, <sup>1</sup>School of Pharmacy, University of Washington, Seattle, WA, USA; <sup>2</sup>Centre for Health Economics, University of York, York, England; <sup>3</sup>School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

**PMC2 RUNNING COST OF TREATING A PATIENT IN A GENERAL MEDICAL WARD IN SULTAN QABOOS UNIVERSITY HOSPITAL IN OMAN**

Al-Zakwani I, Rao S, Al-Riyamy K, Balkhair A, Sultan Qaboos University Hospital, Muscat, Oman

**PMC3 SURVIVAL GAINS AND DEGREE OF THERAPEUTIC INNOVATION**

Messori A, Trippoli S, Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy

**PMC4 LINKING HROOLS TO LARGE NATIONAL DATA SETS: EUROQOL AND HUI INDICES PRIVATE**

Rizzo JA, Sindelar JL<sup>1</sup>, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

**PMC5 USING A SURROGATE SAMPLE TO DERIVE PATIENT PREFERENCES FOR A COST-UTILITY ANALYSES IN A RANDOMIZED CLINICAL TRIAL**

Lustig S<sup>1</sup>, Lispcomb J<sup>2</sup>, Salsburg D<sup>3</sup>, Trost C<sup>1</sup>, Turner R<sup>5</sup>, <sup>1</sup>Pfizer, Groton, CT, USA, <sup>2</sup>Duke University, Durham, NC, USA, <sup>3</sup>New London, CT, USA, <sup>4</sup>Phase V Technologies, Inc., Wellesley Hills, MA, USA

**PMC6 ADVANCED SENSITIVITY ANALYSIS BY THE INTEGRATION OF POINT-SENSITIVITY AND RANGE-SENSITIVITY USING PROBABILITY DISTRIBUTIONS**

Mark J.C. Nuijten, The Lewin Group, Hoofddorp, The Netherlands

## 8.30 – 9.30 CONTRIBUTED WORKSHOPS – SESSION 2

### TRACK 1 : DECISION SUPPORT SYSTEMS & MODELS

#### W11 DECISION ANALYSIS IN CANCER THERAPY, A NEW WAY FOR EVALUATION OUTCOMES WITH THE ANALYTIC HIERARCHY PROCESS (AHP)

Reibnitz C, Silva Saavedra, M, School of Public Health, University of Bielefeld, Bielefeld, Germany

#### W12 DEVELOPING INTERACTIVE COMPUTER SOFTWARE FOR EVALUATING THE ECONOMIC AND CLINICAL OUTCOMES OF VARIOUS TREATMENT STRATEGIES

McGhan WF, University of the Sciences in Philadelphia, Philadelphia, PA, USA

### TRACK 2: GUIDELINES & STANDARDS

#### W17 STANDARDIZATION IN THE PUBLIC HEALTH SYSTEM OF RUSSIA: THE FIRST EXPERIENCE

Vorobyev PA<sup>1</sup>, Aksyuk AV<sup>1</sup>, Yakimov OS<sup>1</sup>, Novolodsky VM<sup>1</sup>, Kuzin VF<sup>1</sup>, Kobina SA<sup>2</sup>, <sup>1</sup>Moscow Medical Academy, Laboratory of Outcomes and Standardization Research, Moscow, Russia; <sup>2</sup>Rhône-Poulenc Moscow Representative office, Pharmacoeconomics Department, Moscow, Russia

### TRACK 3: QUALITY OF LIFE ASSESSMENT

#### W18 COMPREHENSIVE GUIDELINES FOR INTERPRETATION AND VALIDATION OF QUALITY OF LIFE QUESTIONNAIRES

Marquis P<sup>1</sup>, Arnold B<sup>1</sup>, Conway K<sup>2</sup>, <sup>1</sup>Mapi Values, Lyon, France, <sup>2</sup>Mapi Research Institute, Lyon, France

### TRACK 4: STUDY METHODS

#### W7 HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS

Trippoli S, Messori A, Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy

#### W14 DESIGNING AN INTERNATIONAL PIGGY-BACK STUDY: PROVIDING THE FOUNDATION

Crawford B<sup>1</sup>, Evans C<sup>2</sup>, <sup>1</sup>MAPI Values, Boston, MA, USA; <sup>2</sup>Astra Pharmaceuticals, Westborough, MA, USA

## 9.30 – 10.30 CONTRIBUTED WORKSHOP – SESSION 2R (SESSION 2 WORKSHOPS ARE REPEATED)

### TRACK 1 : DECISION SUPPORT SYSTEMS & MODELS

#### W11 DECISION ANALYSIS IN CANCER THERAPY, A NEW WAY FOR EVALUATION OUTCOMES WITH THE ANALYTIC HIERARCHY PROCESS (AHP)

Reibnitz C, Silva Saavedra, M, School of Public Health, University of Bielefeld, Bielefeld, Germany

#### W12 DEVELOPING INTERACTIVE COMPUTER SOFTWARE FOR EVALUATING THE ECONOMIC AND CLINICAL OUTCOMES OF VARIOUS TREATMENT STRATEGIES

McGhan WF, University of the Sciences in Philadelphia, Philadelphia, PA, USA

### TRACK 2: GUIDELINES & STANDARDS

#### W17 STANDARDIZATION IN THE PUBLIC HEALTH SYSTEM OF RUSSIA: THE FIRST EXPERIENCE

Vorobyev PA<sup>1</sup>, Aksyuk AV<sup>1</sup>, Yakimov OS<sup>1</sup>, Novolodsky VM<sup>1</sup>, Kuzin VF<sup>1</sup>, Kobina SA<sup>2</sup>, <sup>1</sup>Moscow Medical Academy, Laboratory of Outcomes and Standardization Research, Moscow, Russia; <sup>2</sup>Rhône-Poulenc Moscow Representative office, Pharmacoeconomics Department, Moscow, Russia

### TRACK 3: QUALITY OF LIFE ASSESSMENT

#### W18 COMPREHENSIVE GUIDELINES FOR INTERPRETATION AND VALIDATION OF QUALITY OF LIFE QUESTIONNAIRES

Marquis P<sup>1</sup>, Arnold B<sup>1</sup>, Conway K<sup>2</sup>, <sup>1</sup>Mapi Values, Lyon, France, <sup>2</sup>Mapi Research Institute, Lyon, France

### TRACK 4: STUDY METHODS

#### W7 HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS

Trippoli S, Messori A. Laboratorio SIFO di Farmacoeconomia, c/o Centro Informazione Farmaci, Azienda Ospedaliera Careggi, Florence, Italy

**W14 DESIGNING AN INTERNATIONAL PIGGY-BACK STUDY: PROVIDING THE FOUNDATION**

Crawford B<sup>1</sup>, Evans C<sup>2</sup>, <sup>1</sup>MAPI Values, Boston, MA, USA; <sup>2</sup>Astra Pharmaceuticals, Westborough, MA, USA

**10.30-12.00 THIRD GENERAL SESSION**

**Developing Consensus on Educational Standards, Pharmacoeconomic Evaluations Reporting and Code of Ethics**

Moderator: Jonathan Cooke MPharm, PhD, South Manchester University Hospitals, Manchester, England, UK

**REPORT FROM THE ISPOR US CONSENSUS DEVELOPMENT ADVISORY PANELS ON EDUCATION STANDARDS, CODE OF ETHICS, AND STANDARDIZED REPORTING OF PHARMACOECONOMICS AND OUTCOMES RESEARCH**

Speaker: Jean Paul Gagnon PhD, Director Health Economics Policy, Hoechst Marion Roussel, Kansas City, MO, USA and *ISPOR Consensus Development Chair*

**DEVELOPING CONSENSUS ON EDUCATION STANDARDS, CODE OF ETHICS, AND STANDARDIZED REPORTING OF PHARMACOECONOMICS AND OUTCOMES RESEARCH - A CRITIQUE OF THE US PANEL REPORTS FROM A EUROPEAN PERSPECTIVE**

Speakers: The European Panel

- Werner Brouwer MD, The Netherlands
- Jonathan Cooke MPharm, PhD, MPharm, South Manchester University Hospitals, Manchester, UK
- Michael Drummond PhD, University of York, Centre for Health Economics, York, UK
- Livio Garattini MD, CESAV Centre for Health Economics, Institute for Pharmacological Research, Ranica, Italy
- Bengt G. Jönsson MA, PhD, Stockholm School of Economics, Stockholm, Sweden (invited)
- Karl W. Lauterbach MD, ScD, Institute for Health Economics, University of Cologne, Cologne, Germany
- Frank Peys PhD, Belgium Institute for Health Economics, Brussels, Belgium
- Claude Le Pen PhD, Université Paris-Dauphine, Paris, France
- Hugo Robays, University Hospital Gent, Gent, Belgium
- Joan Rovira PhD, SOIKOS, Department of Economics, University of Barcelona, Barcelona, Spain
- J.Matthias Graf von Schulenberg PhD, Centre for Health Economics and Health System-HSR, University of Hannover, Hannover, Germany

**12.00 -13.00 LUNCH & VIEWING CONTRIBUTED POSTER PRESENTATIONS-SESSION 2**

**13.00 – 14.00 CONTRIBUTED WORKSHOPS – SESSION 3**

**TRACK 1 : DECISION SUPPORT SYSTEMS & MODELS**

**W4 MONTE CARLO SIMULATION IN HEALTH CARE MODELS**

Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA

**W6 THE APPROPRIATENESS OF COMMON MEDICAL DATA SOURCES: RANDOMIZED TRIALS, META-ANALYSES, EPIDEMIOLOGICAL AND OBSERVATIONAL STUDIES FOR PHARMACOECONOMIC ANALYSES**

Hasford J, Sangha O, Department of Medical Informatics, Biometry and Epidemiology, University of Munich, School of Medicine, Munich, Germany

**TRACK 3: QUALITY OF LIFE ASSESSMENT**

**W13 THE USE OF PROXIES TO COLLECT HEALTH CARE RESOURCES AND QUALITY OF LIFE DATA**

Crawford B<sup>1</sup>, Evans C<sup>2</sup>, Abetz L<sup>3</sup>, <sup>1</sup>MAPI Values, Boston, MA, USA; <sup>2</sup>Astra Pharmaceuticals, Westborough, MA, USA; <sup>3</sup>MAPI Values, Cheshire, UK

**TRACK 4: STUDY METHODS**

**W2 ESTIMATING DRUG EFFECTS: FROM CLINICAL TRIAL RESULTS TO ACTUAL PRACTICE**

Caro JJ<sup>1</sup>, Migliaccio-Walle K<sup>1</sup>, Thizon de Gaulle I<sup>2</sup>, Coniglio A<sup>2</sup>, <sup>1</sup>Caro Research, Concord, MA, USA; <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA; <sup>3</sup>Sanofi, Paris, France

- W3 ESTIMATING POPULATION BUDGET AND HEALTH IMPACTS OF NEW TREATMENTS**  
Mauskopf J, Research Triangle Institute, Research Triangle Park, NC, USA
- W9 ECONOMIC EVALUATION OF REHABILITATION PROGRAMS: THE PERSPECTIVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY**  
Seitz R<sup>1</sup>, Wasem J<sup>2</sup>, Krauth C<sup>3</sup>, <sup>1</sup>Department for Health Economics, University of Ulm, Ulm, Germany; <sup>2</sup>Institute for Medical Information Management, Biometrics and Epidemiology, University of Munich, Munich, Germany; <sup>3</sup>Department for Social Medicine and Epidemiology, University of Hannover, Hannover, Germany

## 14.00 – 15.00 CONTRIBUTED WORKSHOP – SESSION 3R (SESSION 3 WORKSHOPS ARE REPEATED)

### TRACK 1: DECISION SUPPORT SYSTEMS & MODELS

- W4 MONTE CARLO SIMULATION IN HEALTH CARE MODELS**  
Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA
- W6 THE APPROPRIATENESS OF COMMON MEDICAL DATA SOURCES: RANDOMIZED TRIALS, META-ANALYSES, EPIDEMIOLOGICAL AND OBSERVATIONAL STUDIES FOR PHARMACOECONOMIC ANALYSES**  
Hasford J, Sangha O, Department of Medical Informatics, Biometry and Epidemiology, University of Munich, School of Medicine, Munich, Germany

### TRACK 3: QUALITY OF LIFE ASSESSMENT

- W13 THE USE OF PROXIES TO COLLECT HEALTH CARE RESOURCES AND QUALITY OF LIFE DATA**  
Crawford B<sup>1</sup>, Evans C<sup>2</sup>, Abetz L<sup>3</sup>, <sup>1</sup>MAPI Values, Boston, MA, USA; <sup>2</sup>Astra Pharmaceuticals, Westborough, MA, USA; <sup>3</sup>MAPI Values, Cheshire, UK

### TRACK 4: STUDY METHODS

- W2 ESTIMATING DRUG EFFECTS: FROM CLINICAL TRIAL RESULTS TO ACTUAL PRACTICE**  
Caro JJ<sup>1</sup>, Migliaccio-Walle K<sup>1</sup>, Thizon de Gaulle P<sup>2</sup>, Coniglio A<sup>2</sup>, <sup>1</sup>Caro Research, Concord, MA, USA; <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA; <sup>3</sup>Sanofi, Paris, France
- W3 ESTIMATING POPULATION BUDGET AND HEALTH IMPACTS OF NEW TREATMENTS**  
Mauskopf J, Research Triangle Institute, Research Triangle Park, NC, USA
- W9 ECONOMIC EVALUATION OF RAHABILITATION PROGRAMS: THE PERSPECTIVE OF SOCIAL OLD AGE INSURANCE FUNDS IN GERMANY**  
Seitz R<sup>1</sup>, Wasem J<sup>2</sup>, Krauth C<sup>3</sup>, <sup>1</sup>Department for Health Economics, University of Ulm, Ulm, Germany; <sup>2</sup>Institute for Medical Information Management, Biometrics and Epidemiology, University of Munich, Munich, Germany; <sup>3</sup>Department for Social Medicine and Epidemiology, University of Hannover, Hannover, Germany

## 15.00 - 16.30 FOURTH GENERAL SESSION

### Using Disease Management to Deliver Cost-Effective Health Care - Focusing on Diabetes

Moderator: Karl Lauterbach MD, ScD, Institute for Health Economics at the University of Cologne

#### DIABETES MANAGEMENT IN US MANAGED CARE HEALTH PLANS

Speaker: Gregory P. Gilmet MD, MPH, Medical Director, Quality Management, Blue Care Network of Michigan, Southfield, MI, USA

#### DIABETES DISEASE MANAGEMENT PROGRAMS THAT WORK AND THOSE THAT DON'T

Speaker: Jean-Philippe Assal MD, WHO Collaborating Centre for Reference and Research in Diabetes Education, University Hospital, Geneva, Switzerland

#### WORKING AT THE POPULATION LEVEL: THE FUTURE OF DIABETES MANAGEMENT

Speaker: Andrew Morris, MD, Director of Diabetes Research, MEMO, Ninewells Hospital and Medical School, Dundee Teaching Hospitals, Dundee, Scotland, UK


## 16.30 - 17.00 CLOSING REMARKS

Speakers: ISPOR Conference Co-chairs

## HOTEL RESERVATIONS



Contact the Renaissance Köln Hotel in Cologne, Germany by calling (49) 0221 - 20 34 803 or fax (49) 0221-20 34 880. Please make your reservations by October 15, 1998. The rate is DM 225 per room night.



## HOTEL LOCATION

The Hotel is centrally located on the "Friesenplatz" in the heart of the business district of Cologne, the metropolis by the Rhine. The Cathedral can be reached within 10 minutes walk.

### THE RENAISSANCE KÖLN HOTEL IS:

- 15 km to the Cologne/Bonn Airport
- 200 m to the underground
- 1 km to the railway station
- 3 km to the trade fair grounds

## TOUR PROGRAMS

A 3-hour tour program with a local guide will be available from 10.00 to 13.00 on Saturday, December 12 and Sunday, December 13 to visit the world-renown Cathedral along the banks of the Rhine River as well as the most interesting sites in and around Cologne. For more information, please contact Jennifer Olson, ISPOR, Director of Meetings & Conventions at 609-252-1305 ext. 107 or via e-mail at [jolson@ispor.org](mailto:jolson@ispor.org).



## AIRLINE DISCOUNT

ISPOR has arrangements with US Airways for discounted travel through Frankfurt, Germany to the ISPOR Inaugural European Conference in Cologne, Germany. For discounted rate information, call 800-451-7208 between the hours of 8:00 am and 9:00 pm Eastern Standard Time. Please refer to Gold File # 22 1307 52.

***With this program you can receive the following discounts:***

- 5% off the lowest fare available
- 10% off unrestricted coach class tickets
- 10% off the lowest rate available if booked 60 days prior to flight
- 15% off unrestricted coach class tickets if booked 60 days prior to

## EXHIBITORS

Exhibitors will be promoting pharmaceutical products, resources and services for the pharmaco-economic and outcomes researcher, and health care decision tools. If your organization would like to exhibit, please contact Jennifer Olson, ISPOR Director Meetings & Conventions at [jolson@ispor.org](mailto:jolson@ispor.org) or 609-252-1305 for more detailed information.

# Inaugural *European* Conference

## REGISTRATION FORM

DECEMBER 10, 11 & 12, 1998 • RENAISSANCE KÖLN HOTEL • COLOGNE, GERMANY

NAME \_\_\_\_\_

DEGREES \_\_\_\_\_

POSITION \_\_\_\_\_

INSTITUTION \_\_\_\_\_

MAILING ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_ COUNTRY \_\_\_\_\_

TELEPHONE \_\_\_\_\_ FAX \_\_\_\_\_ E-MAIL \_\_\_\_\_

### MEETING REGISTRATION: (Check appropriate box)

(includes lunch, coffee breaks, all meeting sessions, exhibits, and poster sessions)

### CONFERENCE

#### ACADEMIA, CLINICAL PRACTICE & GOVERNMENT EMPLOYEES

#### US DOLLARS

#### GERMAN MARK

Registration Before November 1, 1998

US\$ 200

DM 360

Registration After November 1, 1998

US\$ 300

DM 540

#### ALL OTHERS

#### ISPOR MEMBERS

#### NON-MEMBERS\*

Registration Before November 1, 1998

US\$ 450

DM 810

US\$ 575

DM 1035

Registration After November 1, 1998

US\$ 550

DM 990

US\$ 675

DM 1215

#### PRE-CONFERENCE SHORT COURSES (@ 4 HRS)

US\$ 100

DM 180

US\$ 100

DM 180

Select ONE of the following courses:

Pharmacoeconomics  Decision Analysis  Meta-analysis  Quality-of-Life Instruments

Registration Before November 1, 1998

US\$ 100

DM 180

US\$ 100

DM 180

Registration After November 1, 1998

US\$ 150

DM 270

US\$ 150

DM 270

#### TOTAL REGISTRATION FEE:

\$ \_\_\_\_\_

DM \_\_\_\_\_

\$ \_\_\_\_\_

DM \_\_\_\_\_

### PAYMENT:

CHARGE TO:  VISA  MasterCard  American Express

ACCOUNT NAME: \_\_\_\_\_ ACCOUNT NUMBER: \_\_\_\_\_

AUTHORIZED SIGNATURE: \_\_\_\_\_ EXPIRATION DATE: \_\_\_\_\_

Include signature, account number, and expiration date. VISA, MasterCard, American Express will be charged in US dollars. Phone charges will NOT be accepted. Send to: ISPOR, 20 Nassau Street, Suite 307, Princeton, NJ 08542 USA or FAX to: 609-252-1306.

### CASH PAYMENT: Payment may be made in US dollars or German Marks.

**Payment in US dollars:** Payment may be made by check or travelers check. Non-US checks written in US\$ must be written on banks with a US counterpart. Send to: ISPOR, 20 Nassau Street, Suite 307, Princeton, NJ 08542 USA or FAX to: 609-252-1306.

**Payment in German Marks:** Checks written in German Marks must be written on a German bank to: ISPOR or International Society for Pharmacoeconomics and Outcomes Research. Send to: ISPOR, 20 Nassau Street, Suite 307, Princeton, NJ 08542 USA or FAX to: 609-252-1306 or send to: Institute for Health Economics at the University of Cologne, Gleuler Strasse 176-178, D-50935 Cologne, Germany. For bank transfer in German Marks, transfer to: Bank für Sozialwirtschaft Köln, BLZ: 307 205 00, Verwendungszweck: 4620/700/31 ISPOR. Your name must be included on the bank transfer document.

\* When you register as a non-member, you receive ISPOR membership until December 31, 1999 and a one-year subscription to *VALUE IN HEALTH—The Journal of the International Society for Pharmacoeconomics and Outcomes Research*.

**Cancellation fee before November 1, 1998 is US \$100 or DM 180. No refunds will be given after November 1, 1998.**

International Society for Pharmacoeconomics and Outcomes Research

20 Nassau Street, Suite 307, Princeton, New Jersey 08542

Phone: 609-252-1305 Fax: 609-252-1306 E-Mail: [info@ispor.org](mailto:info@ispor.org) Website: <http://www.ispor.org>

---

# Inaugural *European* Conference

*jointly sponsored by the*  
International Society for Pharmacoeconomics and Outcomes Research  
and the University of Cologne

---

Since over **100 Original Research Abstracts** and  
**over 18 Contributed Workshops** will be presented, the  
**CONFERENCE START DATE IS NOW DECEMBER 10TH AT 13.00**

---

## IMPORTANT DATES TO REMEMBER

- Early Registration Deadline: November 1, 1998
- Short Courses Time and Date: December 10, 1998 at 8.00 - 12.00
- ISPOR European Conference NEW START TIME & DATE: December 10, 1998 at 13.00

## ISPOR UPCOMING DATES & EVENTS

- ISPOR 4th Annual International Meeting Call for Abstracts, Submission Deadline: January 20, 1999
  - ISPOR 4th Annual International Meeting: May 23-26, 1999, Crystal City, VA, USA (Washington, DC)
    - ISPOR 2nd Annual European Conference: November 11-13, 1999,  
Sheraton Grand Hotel, Edinburgh, Scotland
- 

International Society for Pharmacoeconomics and Outcomes Research  
20 Nassau Street, Suite 307  
Princeton, NJ 08542



Nonprofit Org.  
U.S. Postage  
**PAID**  
Permit No. 20  
Dayton, NJ  
08810